CN103710465A - 一种乙型肝炎病毒基因分型pcr检测试剂盒 - Google Patents
一种乙型肝炎病毒基因分型pcr检测试剂盒 Download PDFInfo
- Publication number
- CN103710465A CN103710465A CN201310744571.1A CN201310744571A CN103710465A CN 103710465 A CN103710465 A CN 103710465A CN 201310744571 A CN201310744571 A CN 201310744571A CN 103710465 A CN103710465 A CN 103710465A
- Authority
- CN
- China
- Prior art keywords
- type
- primer
- target polynucleotide
- probe sequence
- amplification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700721 Hepatitis B virus Species 0.000 title claims abstract description 69
- 238000001514 detection method Methods 0.000 title claims abstract description 55
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 36
- 238000003752 polymerase chain reaction Methods 0.000 title abstract 7
- 239000000523 sample Substances 0.000 claims abstract description 103
- 230000003321 amplification Effects 0.000 claims abstract description 51
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 51
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 50
- 239000002157 polynucleotide Substances 0.000 claims abstract description 50
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 50
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 23
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 23
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 23
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 7
- AFWTZXXDGQBIKW-UHFFFAOYSA-N C14 surfactin Natural products CCCCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 AFWTZXXDGQBIKW-UHFFFAOYSA-N 0.000 claims abstract description 6
- NJGWOFRZMQRKHT-UHFFFAOYSA-N surfactin Natural products CC(C)CCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-UHFFFAOYSA-N 0.000 claims abstract description 6
- NJGWOFRZMQRKHT-WGVNQGGSSA-N surfactin C Chemical compound CC(C)CCCCCCCCC[C@@H]1CC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-WGVNQGGSSA-N 0.000 claims abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims description 51
- 239000000243 solution Substances 0.000 claims description 35
- 238000012360 testing method Methods 0.000 claims description 28
- 238000011144 upstream manufacturing Methods 0.000 claims description 24
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 235000011178 triphosphate Nutrition 0.000 claims description 6
- 239000001226 triphosphate Substances 0.000 claims description 6
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 6
- 239000013642 negative control Substances 0.000 claims description 5
- 239000013641 positive control Substances 0.000 claims description 5
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 claims description 5
- 239000005549 deoxyribonucleoside Substances 0.000 claims description 4
- 239000011535 reaction buffer Substances 0.000 claims description 4
- 108091028664 Ribonucleotide Proteins 0.000 claims description 2
- 239000002336 ribonucleotide Substances 0.000 claims description 2
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 22
- 210000002966 serum Anatomy 0.000 abstract description 6
- 238000004393 prognosis Methods 0.000 abstract description 4
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 238000012502 risk assessment Methods 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract 2
- 101150076489 B gene Proteins 0.000 abstract 1
- 101150111062 C gene Proteins 0.000 abstract 1
- 101150097493 D gene Proteins 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000002651 drug therapy Methods 0.000 abstract 1
- 235000011164 potassium chloride Nutrition 0.000 abstract 1
- 239000001103 potassium chloride Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 11
- 208000002672 hepatitis B Diseases 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 8
- 102100037111 Uracil-DNA glycosylase Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 4
- 101710142246 External core antigen Proteins 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000001917 fluorescence detection Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 239000012925 reference material Substances 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000037029 cross reaction Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000703 high-speed centrifugation Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003771 laboratory diagnosis Methods 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 206010059193 Acute hepatitis B Diseases 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 101150010882 S gene Proteins 0.000 description 1
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 1
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000037628 acute hepatitis B virus infection Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000009863 impact test Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310744571.1A CN103710465B (zh) | 2013-12-30 | 2013-12-30 | 一种乙型肝炎病毒基因分型pcr检测试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310744571.1A CN103710465B (zh) | 2013-12-30 | 2013-12-30 | 一种乙型肝炎病毒基因分型pcr检测试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103710465A true CN103710465A (zh) | 2014-04-09 |
CN103710465B CN103710465B (zh) | 2015-02-04 |
Family
ID=50403815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310744571.1A Active CN103710465B (zh) | 2013-12-30 | 2013-12-30 | 一种乙型肝炎病毒基因分型pcr检测试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103710465B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105018468A (zh) * | 2015-07-28 | 2015-11-04 | 宝瑞源生物技术(北京)有限公司 | 乙型肝炎病毒基因分型核酸检测试剂盒(荧光pcr法) |
CN105039599A (zh) * | 2015-08-21 | 2015-11-11 | 北京鑫诺美迪基因检测技术有限公司 | 分型定性检测乙型肝炎病毒的引物、探针及试剂盒 |
RU2633755C1 (ru) * | 2016-11-15 | 2017-10-17 | Федеральное бюджетное учреждение науки "Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии имени Пастера" (ФБУН НИИ эпидемиологии и микробиологии имени Пастера) | Способ выявления в биологическом материале ДНК вируса гепатита В при низкой вирусной нагрузке на основе двухэтапной ПЦР |
CN109457049A (zh) * | 2018-12-07 | 2019-03-12 | 迈克生物股份有限公司 | 一种用于乙型肝炎病毒基因分型检测的组合物、试剂盒及其方法 |
CN112813204A (zh) * | 2021-03-10 | 2021-05-18 | 北京康美天鸿生物科技有限公司 | 一种对乙型肝炎病毒进行基因分型的荧光pcr试剂盒 |
CN114250325A (zh) * | 2021-12-31 | 2022-03-29 | 广西壮族自治区疾病预防控制中心 | 快速检测乙型肝炎病毒9个基因型的引物、探针、试剂盒和方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102174660A (zh) * | 2011-02-25 | 2011-09-07 | 湖南圣湘生物科技有限公司 | 乙型肝炎病毒荧光定量pcr检测试剂盒 |
CN102559933A (zh) * | 2012-01-18 | 2012-07-11 | 泰普生物科学(中国)有限公司 | 乙型肝炎病毒基因分型的基因芯片和试剂盒及方法 |
CN102586473A (zh) * | 2012-01-12 | 2012-07-18 | 泰普生物科学(中国)有限公司 | 一种乙型肝炎病毒基因分型pcr检测试剂盒 |
CN102796828A (zh) * | 2007-10-30 | 2012-11-28 | 株式会社东芝 | 用于检测乙型肝炎病毒的抗药性株系的核酸引物组、测定试剂盒及检测乙型肝炎病毒的抗药性株系的方法 |
CN103060451A (zh) * | 2013-01-10 | 2013-04-24 | 湖南圣湘生物科技有限公司 | 一种肺炎支原体mp检测试剂盒 |
-
2013
- 2013-12-30 CN CN201310744571.1A patent/CN103710465B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102796828A (zh) * | 2007-10-30 | 2012-11-28 | 株式会社东芝 | 用于检测乙型肝炎病毒的抗药性株系的核酸引物组、测定试剂盒及检测乙型肝炎病毒的抗药性株系的方法 |
CN102174660A (zh) * | 2011-02-25 | 2011-09-07 | 湖南圣湘生物科技有限公司 | 乙型肝炎病毒荧光定量pcr检测试剂盒 |
CN102586473A (zh) * | 2012-01-12 | 2012-07-18 | 泰普生物科学(中国)有限公司 | 一种乙型肝炎病毒基因分型pcr检测试剂盒 |
CN102559933A (zh) * | 2012-01-18 | 2012-07-11 | 泰普生物科学(中国)有限公司 | 乙型肝炎病毒基因分型的基因芯片和试剂盒及方法 |
CN103060451A (zh) * | 2013-01-10 | 2013-04-24 | 湖南圣湘生物科技有限公司 | 一种肺炎支原体mp检测试剂盒 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105018468A (zh) * | 2015-07-28 | 2015-11-04 | 宝瑞源生物技术(北京)有限公司 | 乙型肝炎病毒基因分型核酸检测试剂盒(荧光pcr法) |
CN105039599A (zh) * | 2015-08-21 | 2015-11-11 | 北京鑫诺美迪基因检测技术有限公司 | 分型定性检测乙型肝炎病毒的引物、探针及试剂盒 |
RU2633755C1 (ru) * | 2016-11-15 | 2017-10-17 | Федеральное бюджетное учреждение науки "Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии имени Пастера" (ФБУН НИИ эпидемиологии и микробиологии имени Пастера) | Способ выявления в биологическом материале ДНК вируса гепатита В при низкой вирусной нагрузке на основе двухэтапной ПЦР |
CN109457049A (zh) * | 2018-12-07 | 2019-03-12 | 迈克生物股份有限公司 | 一种用于乙型肝炎病毒基因分型检测的组合物、试剂盒及其方法 |
CN109457049B (zh) * | 2018-12-07 | 2021-12-03 | 迈克生物股份有限公司 | 一种用于乙型肝炎病毒基因分型检测的组合物、试剂盒及其方法 |
CN112813204A (zh) * | 2021-03-10 | 2021-05-18 | 北京康美天鸿生物科技有限公司 | 一种对乙型肝炎病毒进行基因分型的荧光pcr试剂盒 |
CN114250325A (zh) * | 2021-12-31 | 2022-03-29 | 广西壮族自治区疾病预防控制中心 | 快速检测乙型肝炎病毒9个基因型的引物、探针、试剂盒和方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103710465B (zh) | 2015-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103710465B (zh) | 一种乙型肝炎病毒基因分型pcr检测试剂盒 | |
CN101701267B (zh) | 乙型肝炎病毒荧光定量pcr检测试剂盒及其应用 | |
CN102174660B (zh) | 乙型肝炎病毒荧光定量pcr检测试剂盒 | |
CN103060473B (zh) | 一种疱疹类病毒ebv检测试剂盒 | |
WO2022068079A1 (zh) | 一种基于微滴式数字pcr技术的乙型肝炎病毒t216c突变检测方法 | |
CN104450963A (zh) | 一种hbv dna数字pcr定量检测试剂盒及其应用 | |
CN102586473B (zh) | 一种乙型肝炎病毒基因分型pcr检测试剂盒 | |
CN109777893A (zh) | 微滴式数字pcr隐匿性乙肝病毒检测试剂盒 | |
CN103740832A (zh) | 一种新型隐球菌检测试剂盒 | |
CN103773897B (zh) | 一种用于丙型肝炎病毒核酸检测和基因分型的多重荧光pcr检测试剂盒及其应用 | |
CN103122396B (zh) | 一种人巨细胞病毒hcmv检测试剂盒 | |
CN105861743B (zh) | 一种含内标的用于检测丙型肝炎病毒核酸的试剂盒和检测方法 | |
CN105400903A (zh) | 用于检测hbv核酸的引物组、探针、试剂盒及检测样本中hbv核酸的方法 | |
CN105420410A (zh) | 检测乙型肝炎病毒核酸的引物组、探针、试剂盒和检测方法 | |
CN102559930A (zh) | 一种荧光定量rt-pcr检测丙型肝炎病毒的试剂盒 | |
CN108950082A (zh) | 一种乙型肝炎病毒核酸定量检测试剂盒 | |
CN107604096B (zh) | 一种用于乙型肝炎病毒检测的核酸序列及试剂盒 | |
CN105039599A (zh) | 分型定性检测乙型肝炎病毒的引物、探针及试剂盒 | |
CN100422344C (zh) | 乙型肝炎病毒基因分型的荧光pcr检测方法及其试剂盒 | |
CN101812537A (zh) | 同时检测乙型肝炎病毒三种核苷酸类似物耐药位点的方法及其试剂盒 | |
CN103074429B (zh) | 解脲脲原体uu检测试剂盒 | |
CN103088151B (zh) | 用于乙型肝炎病毒四色荧光定量pcr检测的试剂盒及应用 | |
CN111676315A (zh) | 检测新型冠状病毒ORF1ab基因的引物和探针及其试剂盒和方法 | |
CN115323075B (zh) | 一种检测鸡传染性支气管炎病毒及基因分型的rt-raa引物探针组、试剂盒及其应用 | |
CN110241264A (zh) | 一种乙型肝炎病毒(hbv)dna定量检测试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HUNAN SHENGWEIER MEDICAL INSPECTION CO., LTD. Free format text: FORMER OWNER: HUNAN SHENGXIANG BIOLOGICAL TECHNOLOGY CO., LTD. Effective date: 20141119 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20141119 Address after: 410012, No. 680, Lu Song Road, Changsha hi tech Development Zone, Hunan Applicant after: Hunan company limited of Sheng Weier medical test institute Address before: 410012 No. 680, Lu Song Road, hi tech Industrial Development Zone, Hunan, Changsha Applicant before: Sansure Biotech Inc. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HUNAN SHENGXIANG BIOLOGICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: HUNAN SHENGWEIER MEDICAL INSPECTION CO., LTD. Effective date: 20150526 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150526 Address after: 410012, No. 680, Lu Song Road, hi tech Development Zone, Hunan, Changsha Patentee after: Sansure Biotech Inc. Address before: 410012, No. 680, Lu Song Road, Changsha hi tech Development Zone, Hunan Patentee before: Hunan company limited of Sheng Weier medical test institute |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Hepatitis B virus genotyping PCR (polymerase chain reaction) test kit Effective date of registration: 20170711 Granted publication date: 20150204 Pledgee: Ningbo free trade zone Terry with equity investment partnership (limited partnership)|Suzhou equity equity investment center (limited partnership)|Ningbo Meishan Bonded Port District, Jun and equity investment partnership (limited partnership)|Chen Bang Pledgor: Hunan Gene Technology Co.|Hunan San Xiang Biological Technology Co. Ltd. Registration number: 2017430000042 |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 410012 No. 680, Lu Song Road, hi tech Industrial Development Zone, Hunan, Changsha Patentee after: Shengxiang Biotechnology Co., Ltd Address before: 410012, No. 680, Lu Song Road, hi tech Development Zone, Hunan, Changsha Patentee before: Sansure Biotech Inc. |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200217 Granted publication date: 20150204 Pledgee: Suzhou Lirui equity investment center (limited partnership)|Triton equity investment partnership (limited partnership)|JUNHE Tongrui equity investment partnership (limited partnership)|Chenbang Pledgor: SANSURE BIOTECH Inc. Registration number: 2017430000042 |